Pentax 2005 Annual Report Download - page 23

Download and view the complete annual report

Please find page 23 of the 2005 Pentax annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 79

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79

In 2004, Hoya introduced a yellow-type soft lens that allows patients to recover their sight with a
more natural color cast and that has the added benefit of cutting UV light. We have also commenced
sales in Japan and Europe of an injector cartridge to make surgery even easier. Such developments in
performance and safety have been well received in the market. Sales have continued to grow soundly
in the Japanese market. Hoya has always worked in cooperation with hospitals and specialist
ophthalmology clinics so that its development efforts precisely reflect the needs of the medical
community. This enables Hoya to fulfill its mission of providing patients with high-quality products as
quickly as possible.
In the global market too, Hoya has been energetically developing its IOL business, and sales have
already commenced in Germany, France, Italy, Spain and the United Kingdom. Preparations are also
under way to gain U.S. Food and Drug Administration (FDA) certification by 2007. In Asia, sales have
begun in South Korea, China, Malaysia and Singapore. The newly established IOL plant in Singapore
started shipments to Europe in October 2004, and exports to Japan are anticipated to begin during
2005. Evaluative trials of Hoya’s IOLs are being conducted at a national ophthalmic hospital in
Singapore, and Hoya hopes this will be a springboard for expansion of the business into other Asian
countries.
The size of the global IOL market is currently around ¥100 billion, and within five years it is
expected to expand by 150%. There is potential for the development of prescription IOLs that
include eyesight correction, and because this may even engulf the market for eyeglasses and contact
lenses, further growth is almost a certainty.

IOL injector
HOYA Injector System HOYA-IS
Source:
Journal of Community Eye Health
International Resource Centre, International Centre of Eye Health
Global Estimate of the Number of Eyes with
< 6/60 Due to Cataracts
(Millions)
250
200
150
100
50
0
1980199020002010 2020
Health Care Division